Compare Ferrari NV (RACE) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ferrari NV vs Summit Therapeutics Inc — how do they compare? Ferrari NV trades at $389.37 (market cap $67.35B), while Summit Therapeutics Inc trades at $17.45 (market cap $13.71B). The key difference: Ferrari NV is far larger — about 4.9× Summit Therapeutics Inc's market cap, and Ferrari NV pays a 1.09% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ferrari NV for 126 Days and Summit Therapeutics Inc for 16 Days on average.
| RACE | SMMT | |
|---|---|---|
Market Cap | $67.35B | $13.71B |
Volume | 390,618 | 6,173,057 |
Sector | Consumer Cyclical | Health |
52-Week High | $436.54 | $26.38 |
52-Week Low | $314.63 | $12.43 |
Typical Hold Time | 126 Days | 16 Days |
Enterprise Value | $69.22B | $13.04B |
Dividend Yield | 1.09% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ferrari (RACE) trades at $388.77, up 0.62% today, with a bearish technical signal but strong fundamentals. The stock has beaten earnings estimates for three consecutive quarters, with Q3 2026 results pending. Revenue grew to $7.15 billion in 2025, and net income margin remains robust at 22.25%. The company is executing a share buyback program and expanding partnerships, such as with Rakuten effective 2027.
The outlook is positive given analyst consensus of $462.75 price target and 73.69% buy ratings. Risks include high valuation multiples and exposure to economic cycles. Institutional interest is rising, but technical indicators suggest near-term resistance at $390.
Summit Therapeutics (SMMT) trades at $17.44, down 2.84% on the day, with a bullish technical signal from moving averages and strong analyst support. The company shows no revenue but secured a major $2 billion strategic investment from AstraZeneca in September 2026 to advance its cancer drug ivonescimab, driving recent stock volatility and media attention. Financials reflect a pre-revenue biotech profile with significant losses, negative ROE of -192.5%, and cash flow supported by financing activities.
The outlook hinges on clinical success with ivonescimab, offering substantial upside to the $29.33 consensus price target if trials succeed, but high execution risk remains given the lack of revenue and deep losses. Investors face binary outcomes dependent on drug approval and commercialization timelines amid competitive oncology pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ferrari NV
Ferrari engineers and manufactures some of the world's most expensive exotic sports cars. The Ferrari brand is synonymous with Formula One racing, exclusivity, Italian design, and state-of-the-art technology. Ferrari also has a captive finance company that provides funding for dealers and clients.
Read more on RACE →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
